In a win for Re­gen­eron, No­var­tis' sy­ringe for AMD drug de­clared 'un­patentable'

Re­gen­eron has won a patent case against Swiss phar­ma gi­ant No­var­tis over the de­liv­ery sys­tem for its eye drug Eylea.

The US Patent Tri­al and Ap­peal Board ruled that No­var­tis’ pre-filled sy­ringe for in­ject­ing its eye med­ica­tion Lu­cen­tis was “un­patentable” and hand­ed the vic­to­ry to Re­gen­eron and its AMD drug Eylea.

In the ini­tial com­plaint in 2020, No­var­tis al­leged to the US In­ter­na­tion­al Trade Com­mis­sion that cer­tain pre-filled sy­ringes for the in­trav­it­re­al in­jec­tion, and ul­ti­mate­ly Re­gen­eron’s de­liv­ery sys­tem for Eylea, were in­fring­ing on No­var­tis’ patent. Re­gen­eron filed a pe­ti­tion to re­view No­var­tis’ claims in 2021.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN